BCL2 and B-cell chronic lymphocytic leukemia: Targeting this anti-apoptosis pathway using Bcl-2 inhibitors such as venetoclax, is a faithful alternative for treatment of resistant and refractory CLL as well as other B cell malignancies (18, 19).